Business Context and Reporting Period
This Form 8-K was filed by PerkinElmer, Inc. (Note: The request metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.) on January 7, 2021. The report discloses a material corporate event involving the execution of an Implementation Agreement to acquire Oxford Immunotec Global PLC ("Oxford").
Key Financial Metrics
This filing is a Current Report regarding a corporate transaction and does not contain periodic financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, or liquidity are not provided in this document.
Material Changes
- Acquisition Announcement: On January 7, 2021, PerkinElmer and Oxford announced the execution of an Implementation Agreement for PerkinElmer to acquire Oxford.
- Transaction Structure: The acquisition will be implemented via a scheme of arrangement sanctioned by the U.K. High Court of Justice under Part 26 of the U.K. Companies Act 2006.
- Securities Involved: The filing lists PerkinElmer's registered securities, including Common Stock (PKI), 1.875% Notes due 2026 (PKI 21A), and 0.600% Notes due 2021 (PKI 21B).
Guidance, Outlook, and Risks
Outlook and Forward-Looking Statements: The filing includes standard cautionary language regarding forward-looking statements, noting that estimates for future earnings, cash flow, and revenue growth are based on current assumptions and may not prove correct. No specific financial guidance or projections for the combined entity are included in this text.
Risks and Contingencies: The transaction is subject to several closing conditions and risks, including:
- Receipt of requisite approvals from Oxford's shareholders.
- Sanction of the Scheme by the U.K. Court.
- Uncertainties regarding the timing of consummation.
- Potential disruption to business operations and retention of key employees.
- Impact of the COVID-19 pandemic on sales and operations.
- Regulatory compliance and changes in healthcare industry regulations.
- Fluctuations in global economic and political environments, including the U.K.'s withdrawal from the European Union.
Management Commentary: Investors are urged to read the forthcoming scheme document and proxy statement for detailed information. Voting decisions should be made solely based on those documents when available.
Investor Verification Checklist
- Verify the final terms of the acquisition in the upcoming scheme document and proxy statement.
- Confirm the status of shareholder approvals and U.K. Court sanctions required to close the deal.
- Review the "Risk Factors" sections in the most recent Form 10-Q and 10-K filings for both PerkinElmer and Oxford.
- Monitor for potential disruptions to ongoing business operations during the integration period.
- Check for updates on the impact of the COVID-19 pandemic on the specific markets served by Oxford.